I am fascinated by the ways in which technology can improve our health. I like to think about breakthroughs — devices, drugs, mHealth, SaaS — and the forces that shape how we develop + deploy these tools in the pursuit of broader public health goals.

* * *

I am a healthcare investor at Bain Capital Ventures. Prior to that, I worked at the White House on health reform and the World Health Organization on infectious disease policy. I also worked at a biotech company, helping to develop a new drug for tuberculosis (TMC-207), and at Blackstone, where I focused on helping distressed companies. I graduated from Harvard, where I studied Biomedicine and published some of my work in ScienceNature Biotech, and the New England Journal of Medicine.



Our paper in Science examines the past and future of antibiotic R&D. To sketch a fuller picture of the landscape of antimicrobial innovation, we merged individual compound data from 1990 to 2012 and fit our data to accelerated failure time models... (see blog post; see Science article)

Our paper in Science examines the past and future of antibiotic R&D. To sketch a fuller picture of the landscape of antimicrobial innovation, we merged individual compound data from 1990 to 2012 and fit our data to accelerated failure time models... (see blog post; see Science article)